TrialKidney3602024

Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.

Hong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.